Pipeline

nCage is developing a series of best-in-class vaccines using our TRAP-Cage synthetic VLP platform.

Protein cages are synthetic virus-like particles (VLPs), that can be used to display biological material on their surface, or transport molecules such as nucleic acids or proteins into the interior of the cell. Our cages are programmable and have significant potential as both drug delivery systems and vaccines.
Product
Stage of Development
Rationale for Market Entry
Phase Start Date
Partner
Combo RSV/hMPV Vaccine
Design of VLP
• There are currently no vaccines for hMPV

• RSV vaccines are yet to be trialed in large populations and limitedoptions for patients
2026
Combo Covid/Flu Vaccine
Challenge AnimalExperiments
• Elderly patients are recommended to have both Covid and Flu boosters

• No combo option available
2026
Lyme Disease Vaccine
Design of VLP
• There  are currently no vaccine for Lyme Disease

• Growing problem in the US and Western Europe

• Long term complications from the disease
2027